Summary
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics).
O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS). It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma. The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA. The main characteristics of O2L-001 are thus the following:
- EASY. simplified model of administration (unique injection)
- EFFICIENT. better thrombolytic effect on best translational model (vs gold standard)
- SAFE. reduced side effect (bleeding and neurotoxoxicity vs gold standard)
O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS). It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma. The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA. The main characteristics of O2L-001 are thus the following:
- EASY. simplified model of administration (unique injection)
- EFFICIENT. better thrombolytic effect on best translational model (vs gold standard)
- SAFE. reduced side effect (bleeding and neurotoxoxicity vs gold standard)
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190188714 |
| Start date: | 01-07-2022 |
| End date: | 30-06-2024 |
| Total budget - Public funding: | 10 535 727,00 Euro - 2 500 000,00 Euro |
Cordis data
Original description
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics).O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS). It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma. The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA. The main characteristics of O2L-001 are thus the following:
- EASY. simplified model of administration (unique injection)
- EFFICIENT. better thrombolytic effect on best translational model (vs gold standard)
- SAFE. reduced side effect (bleeding and neurotoxoxicity vs gold standard)
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Geographical location(s)
